Optimising cancer therapy in the era of technological progress
Findings from latest research reflect emerging opportunities in oncology to refine treatments by challenging current paradigms of care
First trial evidence supports minimal residual disease-guided adjuvant immunotherapy in bladder cancer
In the IMvigor011 trial, ctDNA positivity was reported to be strongly predictive of adjuvant immunotherapy benefit in muscle-invasive bladder cancer
Disitamab vedotin plus immunotherapy almost doubles overall survival in advanced HER2 expressing urothelial cancer
The combination, incorporating the novel antibody–drug conjugate, may transform first-line treatment in the setting, but crucial issues need to be addressed
Triple combination with radioligand therapy improves radiographic progression-free survival in metastatic prostate cancer
Presidential Symposium presentation provides insights into the role of 177Lu-PSMA-617 in the treatment of hormone-sensitive prostate cancer, with results also presented in castration-resistant disease
Is targeted therapy for PTEN-deficient metastatic hormone-sensitive prostate cancer on the horizon?
In the CAPItello281 trial, survival results with capivasertib plus abiraterone are promising, but questions remain on the accurate determination of PTEN loss in patients
Mixed results with enzalutamide in non-metastatic prostate cancer
Enzalutamide failed to deliver in high-risk localised prostate cancer, but improved survival, in combination with leuprolide, in biochemically recurrent prostate cancer
Peri-operative enfortumab vedotin plus pembrolizumab prolongs survival in muscle-invasive bladder cancer
In KEYNOTE-905/EV-303, the combination of an antibody–drug conjugate and immunotherapy showed statistically significant and clinically meaningful improvements in event-free survival and overall survival
Is less more for patients with genitourinary cancers?
Study results support alternative treatment regimens in prostate and urothelial tumours, showing similar efficacy to standard care while reducing treatment burden
Early data presented for a biomarker-guided care of metastatic hormone-sensitive prostate cancer
Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of early testing patients for BRCA and HRR mutations
Machine learning models predict adverse events and survival in patients receiving immunotherapy
New data supports the use of artificial intelligence for the administration of immune-check inhibitors in solid tumours